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Objectives. The aim of this multicenter, multinational, prospec-
tive, observational study was to assess the relative value of
myocardial viability and induced ischemia early after uncompli-
cated myocardial infarction.
Background. Dobutamine–atropine stress echocardiography al-
lows evaluation of rest function (at baseline), myocardial viability
(at low dose) and residual ischemia (peak dose, up to 40 mg with
atropine up to 1 mg) in one test.
Methods. Dobutamine–atropine stress echocardiography was
performed 12 6 5 days (mean 6 SD) after a first uncomplicated
acute myocardial infarction in 778 patients (677 men; mean age
58 6 10 years) with technically satisfactory rest echocardio-
graphic study results. Patients were followed-up for 96 7 months.
Results. Dobutamine–atropine stress echocardiographic find-
ings were positive for myocardial ischemia in 436 of patients
(56%) and negative in 342 (44%). During follow-up, there were 14
cardiac-related deaths (1.8% of the total cohort), 24 (2.9%)
nonfatal myocardial infarctions and 63 (8%) hospital readmis-
sions for unstable angina. One hundred seventy-four patients
(22%) underwent coronary revascularization (bypass surgery or
coronary angioplasty). Spontaneous events occurred in 61 of 436
patients with positive and 40 of 342 patients with negative findings
on dobutamine–atropine stress echocardiography (14% vs. 12%,
p 5 0.3). When only spontaneously occurring events were consid-
ered, the most important predictor was myocardial viability
(chi-square 9.7). Using the Cox proportional hazards model, only
the presence of myocardial viability (hazard ratio [HR] 2.0, p <
0.002) and age (HR 1.03, p < 0.001) were predictive of spontane-
ously occurring events. When only hard cardiac events were
considered, age was the strongest predictor (chi-square 3.6, p 5
0.056), followed by wall motion score index (WMSI) at peak dose
(chi-square 3.3, p 5 0.06) and remote ischemia (chi-square 2.25,
p 5 0.1). When cardiac death was considered, WMSI at peak dose
was the best predictor (HR 9.2, p < 0.0001).
Conclusions. During dobutamine stress, echocardiographic rec-
ognition of myocardial viability is more prognostically important
than echocardiographic recognition of myocardial ischemia for
predicting unstable angina, whereas WMSI at peak stress was the
best predictor of cardiac-related death. Different events can be
recognized with different efficiency by various stress echocardio-
graphic variables.
(J Am Coll Cardiol 1997;29:254–60)
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In patients with myocardial infarction, left ventricular function
at rest (1,2), myocardial viability (3–6) and inducible wall
motion abnormalities (7) have recognized prognostic signifi-
cance. Pharmacologic stress echocardiography with titrated
dobutamine infusion provides the unique opportunity of an
integrated assessment of these three variables: Rest function
can be evaluated at baseline; myocardial viability can be
identified at the low dose stage as a functional improvement in
regions with rest dyssynergy (8); and myocardial ischemia can
be recognized at high doses as wall motion dysfunction (9).
Noninvasive risk stratification of patients recovering from an
uncomplicated myocardial infarction remains a major chal-
lenge for clinical cardiologists (10). To date, data on the
prognostic value of dobutamine stress echocardiography in this
subset of patients are limited (11,12) and have several limita-
tions, thus blunting their impact on clinical practice: small
sample size; the need to include subjective end points, such as
revascularization procedures, to document prognostic power;
the highly selected nature of the patients studied to date and
the inclusion of patients with clinical complications in whom
any form of stress testing may be redundant (10).
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In the present study, the capability of dobutamine–atropine
stress echocardiography for prognostic stratification early after
an acute myocardial infarction was evaluated in a large-scale
multicenter, multinational, observational study design on the
basis of evidence collected by 14 different echocardiographic
laboratories, all with established experience in stress echocar-
diography and meeting the quality control requirements for
stress echocardiographic interpretation (7). A total of 778
patients were evaluated 12 6 5 days (mean 6 SD) after a first
acute myocardial infarction and were followed up for 9 6 7
months.
Methods
Patients. The initial cohort included 1,362 patients admit-
ted to the coronary care unit for episode of acute myocardial
infarction. Of these 1,362, 159 were excluded for continuing
myocardial ischemia, left ventricular failure, shock or impor-
tant cardiac arrhythmias. Of the remaining 1,203 patients, 34
had a technically poor acoustic window at baseline, making
dobutamine–atropine stress echocardiography unfeasible; 224
were excluded for age .75 years; 58 did not undergo stress
testing because of refusal to take the test or for logistic
reasons; 71 experienced a reinfarction. An additional 38
patients were eligible for dobutamine–atropine stress echocar-
diography but were subsequently lost to follow-up. Therefore,
from January 1, 1992 to October 1, 1994, we studied 778
consecutive patients (101 women, 677 men, mean [6SD] age
58 6 10 years) with a clinically uncomplicated first acute
myocardial infarction, baseline echocardiographic findings of
satisfactory quality and available follow-up information. The
primary rest and stress findings in the study patients are
reported in Table 1. All patients underwent dobutamine–
atropine stress echocardiography after 12 6 5 days from a first
uncomplicated acute myocardial infarction (no continuing
myocardial ischemia, left ventricular failure, shock or impor-
tant cardiac arrhythmias). It is known that these features
identify a high risk subset on the basis of clinical characteristics
alone and that specialized noninvasive testing has the greatest
potential independent value for risk stratification in patients
without these clinical features (10). According to individual
needs and physician choices, 648 patients were evaluated after
discontinuation of antianginal drugs, and 130 were evaluated
during antianginal treatment (nitrates or calcium antagonists
or beta-adrenergic blocking agents, alone or in combination).
Dobutamine–atropine stress echocardiography. After a
rest electrocardiogram (ECG) and echocardiogram were ac-
quired, intravenous access was secured, and dobutamine was
infused with 3-min dose increments, starting from 5 mg/kg body
weight per min and increasing to 10, 20, 30, 40 mg/kg under
continuous ECG and echocardiographic monitoring. When no
end point was reached, atropine (in four divided doses of
0.25 mg up to a maximum of 1 mg) was added to the continuing
40-mg/kg dobutamine infusion. Regional wall motion was
assessed according to the recommendations of the American
Society of Echocardiography with a 16-segment model (13). In
all studies, segmental wall motion was semiquantitatively
graded as follows: normal 5 1; hypokinetic, marked reduction
of endocardial motion and thickening 5 2; akinetic, virtual
absence of inward motion and thickening 5 3; and dyskinetic,
paradoxic wall motion away from the center of the left
ventricle in systole 5 4. The wall motion score index (WMSI)
was derived by dividing the sum of individual segment scores
by the number of interpretable segments (13). Test positivity
was defined as the occurrence of at least one of the following
conditions: 1) new dyssynergy in a region with normal rest
function (i.e., normokinesia becoming hypokinesia, akinesia or
dyskinesia); 2) worsening of rest dyssynergy (i.e., hypokinesia
becoming akinesia or dyskinesia; rest akinesia becoming dys-
kinesia was not considered a positivity criterion) (14); 3)
biphasic response of a rest dyssynergy (i.e., hypokinesia show-
ing normal function at low dose with a following deterioration
at high dose; or akinesia becoming hypokinesia at low dose and
returning to the initial condition at high dose) (15). Test
positivity was defined as “remote” ischemia when the develop-
ment of asynergy was not directly adjacent to the infarct area
and was assumed to be related to an another vascular region
(16). Nonechocardiographic diagnostic end points were the
following (17): peak atropine dose; 85% of target heart rate;
achievement of conventional (severe chest pain or diagnostic
ST segment changes, or both). The test was also stopped, in the
absence of diagnostic end points, for one of the following
reasons of submaximal, nondiagnostic test results (17): 1)
intolerable symptoms; and 2) limiting asymptomatic side ef-
fects, including a) hypertension (systolic blood pressure
.220 mm Hg; diastolic blood pressure .120 mm Hg); b)
Abbreviations and Acronyms
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
HR 5 hazard ratio
WMSI 5 wall motion score index
Table 1. Rest and Dobutamine Stress Findings in 778 Study Patients
Age (yr) 58 6 10
Range 30–87
Male/female 677/101
Q wave MI 572 (73%)
Non-Q wave MI 206 (26%)
Thrombolytic therapy 450 (58%)
WMSI at rest 1.5 6 0.3
Positive DASE findings 436 (56%)
WMSI at viability assessment 1.46 0.3
WMSI at peak dobutamine 1.76 0.4
ECG changes during DASE 499 (70%)
Chest pain during DASE 107 (14%)
Data presented are mean value 6 SD or number (%) of patients. DASE 5
dobutamine–atropine stress echocardiography; ECG 5 electrocardiographic;
MI 5 myocardial infarction; WMSI 5 wall motion score index.
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hypotension (relative or absolute: .30-mm Hg decrease in
blood pressure); c) supraventricular arrhythmias (supraven-
tricular tachycardia or atrial fibrillation); d) ventricular ar-
rhythmias (ventricular tachycardia; frequent, polymorphous
premature ventricular beats).
The presence of myocardial viability was defined as an
improvement in regional function of 1 grade or more at low
dose dobutamine (up to 10 mg/kg per min; i.e., a hypokinetic
segment becoming normal or an akinetic segment becoming
hypokinetic).
Echocardiographic monitoring was performed throughout
dobutamine infusion and up to at least 5 min after the end of
the infusion. Two-dimensional echocardiographic images were
recorded at baseline and at the end of each dobutamine step.
For each patient, left ventricular function was evaluated at
baseline, at low dose for the assessment of myocardial viability
in dyssynergic segments and at peak stress.
Quality control of stress echocardiographic readings.
Quality control of the diagnostic performance at the different
centers was of critical importance to acquire meaningful
information for the data bank. In the enrolled centers, quality
control was performed according to two criteria, both of which
had to be met to fulfill the quality control requirements (7,17).
The first criterion was tested on a videotape with 20 stress
echocardiographic studies prepared at the coordinating center
(Institute of Clinical Physiology, Pisa). For all 20 studies the
interpretation of two experienced independent observers
(E.P., A.P.) was concordant as to presence and site of dyssyn-
ergy, and the stress results were in full agreement with the
presence and site of coronary stenoses during coronary angiog-
raphy. The unanimous reading of the two observers was
arbitrarily assumed to be the reference standard against which
the interpretations from each participating center were evalu-
ated. The observers from each center interpreted the video-
tape in a blinded manner, with no access to either clinical and
angiographic data or the interpretation of other observers. It
was assumed a priori that the minimal threshold of concor-
dance to satisfy this part of the quality control had to be$90%.
The second criterion consisted of a random sampling of 20
consecutive studies from each contributing center. These 20
studies were examined in blinded manner by an experienced
cardiologist-echocardiographer at each coordinating center
whose reading was arbitrarily assumed to be the reference
standard. It was assumed a priori that the minimal threshold of
concordance to satisfy the quality control criteria had to be
$80%. The lower concordance cutoff is due to the fact that this
second set of tapes was not selected on the basis of the superior
quality but was randomly sampled from each center in a
consecutive manner. All the 14 enrolled centers met the
minimal requirements of quality control.
Follow-up data. Follow-up data were obtained from at
least one of four sources: review of the patient’s hospital
record; personal communication with the patient’s physician
and review of the patient’s chart; telephone interview with the
patient conducted by trained personnel; or patient visits to staff
physicians at regular intervals in the outpatient clinic (7).
Events were defined as cardiac-related death, nonfatal
myocardial infarction and unstable angina. For patients who
died in the hospital or at home, the cause of death was
elucidated from the medical record, the family and the local
physician who signed the death certificate. The definition of
cardiac-related death required documentation of significant
arrhythmias or cardiac arrest, or both, or death attributable to
congestive heart failure or myocardial infarction in the absence
of any other precipitating factors. In case of death out of
hospital for which no autopsy was performed, sudden unex-
pected death was attributed to a cardiac cause. Myocardial
infarction was defined as a cardiac event requiring admission to
the hospital, with development of new ECG changes and
cardiac enzyme level increases. Unstable angina was defined by
accelerating anginal symptoms requiring hospital readmission
(no enzyme level elevation or new wall motion dyssynergy on
the resting echocardiogram or new Q waves on the rest ECG)
or progression of symptoms requiring revascularization.
Therefore, the outcome events were hard cardiac events (de-
fined as cardiac-related death or nonfatal myocardial infarc-
tion) for infarction-free survival and spontaneously occurring
events (death, nonfatal myocardial infarction, unstable angina)
for spontaneous event-free survival. Only the most severe
outcome was considered an end point when follow-up was
censored at revascularization procedures.
There is controversy over whether coronary artery bypass
surgery and coronary angioplasty should be considered cardiac
events. They are likely to reflect the presence of severe disease.
However, the decision to perform these procedures may be
subjective and not by itself an adverse outcome. Therefore, the
data were analyzed after exclusion of revascularization proce-
dures.
Statistical analysis. Results are expressed as mean value6
SD. The individual effects of certain variables on event-free
survival were evaluated with the use of the Cox regression
model (BMDP 2L, Department of Biomathematics, University
of California at Los Angeles, revised 1987). The analysis was
performed according to the unmodified forward-selection
stepwise procedure. In this case, the variables were entered in
to the model on the basis of a computed significance proba-
bility; accordingly, the variable that has the most significant
relation to dependent outcome is selected first for inclusion in
the model, and a solution to the functional form of the
equation is computed. At the second and subsequent steps, the
set of variables remaining at each point is evaluated, and
the most significant is included if it improves the prediction of
the outcome (dependent variable), but in this case this proba-
bility is conditional on the presence of the variable already
selected. The algorithm ceases to select variables when there is
no further significant improvement in the prediction of the
whole model.
Variables selected for examination were age, gender, his-
tory of angina, thrombolysis, Q wave myocardial infarction,
WMSI at rest, WMSI at viability, presence of myocardial
viability, dobutamine–atropine stress echocardiographic posi-
tivity, WMSI at peak dobutamine, dobutamine time (i.e., test
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duration to time of echocardiographically detected ischemia),
remote ischemia.
Continuous variables were compared by the unpaired two-
sample t test. Proportions were compared by the chi-square
statistic; a Fisher exact test was used when appropriate.
Kaplan-Meier life-table estimates of spontaneously occurring
event-free survival was used to summarize the follow-up
experience in these patients and to clarify presentation. Dif-
ferences in survival curves were tested with the Mantel-
Haenzsel statistic. A p value ,0.05 was considered statistically
significant.
Results
The main rest and stress echocardiographic data are re-
ported in Table 1.
Feasibility and tolerability of dobutamine–atropine stress
echocardiography. In 43 patients, the test was submaximal for
occurrence of limiting side effects; the test results of these
patients (6% of all studies) were included in the analysis. Four
patients had a major adverse reaction (ventricular fibrillation
in one, acute myocardial infarction in one, ventricular tachy-
cardia in two, as described in detail previously (17).
Rest echocardiographic findings. The rest WMSI was
1.47 6 0.3. Patients with Q wave infarction (n 5 572, Table 1)
tended to have a higher WMSI than those with non-Q wave
infarction (n 5 206): 1.53 6 0.3 versus 1.30 6 0.3, p 5 NS.
Low dose findings. At the low dose stage (10 mg/kg per min
of dobutamine), the WMSI was 1.4 6 0.3 (p , 0.01 vs. rest
WMSI). Two-hundred sixty-four patients showed echocardio-
graphic evidence of myocardial viability, of whom 205 had a Q
wave infarction with a mean WMSI of 1.62 6 0.3, and 59 had
a non-Q wave infarction with a mean WMSI of 1.456 0.3 (p5
NS).
High dose findings. Four-hundred thirty-six patients had
positive findings on dobutamine–atropine stress echocardiog-
raphy, of whom 379 had new (i.e., a normokinetic region
becoming hypokinetic, akinetic, or dyskinetic) or worsening
(i.e., hypokinetic region becoming akinetic or dyskinetic) dys-
synergy, and 57 had a “biphasic” response (i.e., an akinetic
region at rest improving at low dose and again becoming
akinetic at peak stress).
Among the 342 patients with positive findings on dobutamine–
atropine stress echocardiography, 46 had a positive finding
before or at 9 min (corresponding to a dobutamine dose
#20 mg/kg per min), and 390 had a positive finding after 9 min
(corresponding to a dobutamine dose of 30 to 40 mg/kg per
min, including atropine coadministration with the latter dose).
Three-hundred forty patients had homozonal positivity, and
96 showed remote ischemia. The average WMSI at peak
dobutamine–atropine stress echocardiography was 1.7 6 0.4.
Follow-up data. Patients were followed up for 9 6 7
months (range 1 to 59 months). During the follow-up period,
14 patients died of cardiac-related causes; 24 had a nonfatal
myocardial infarction; 63 developed unstable angina; and 174
underwent a coronary revascularization procedure (bypass
surgery or coronary angioplasty) (Table 2). Patients with
remote ischemia experienced 17 spontaneous events (18%) (4
cardiac-related deaths, 5 nonfatal myocardial infarctions, 8
repeat hospital admissions for unstable angina), whereas pa-
tients with peri-infarct test positivity experienced 39 spontane-
ous events (14%) (6 cardiac-related deaths, 4 nonfatal myo-
cardial infarctions, 29 repeat hospital admissions for unstable
angina). Revascularization procedures were more frequently
undertaken in patients with remote ischemia and in those with
peri-infarct ischemia (36% vs. 26%, p , 0.04). Patients with a
biphasic response (n 5 57) experienced five spontaneous
events (two myocardial infarctions, three repeat hospital ad-
missions for unstable angina).
Cardiac-related death. When cardiac-related death was
considered, there were 10 events in patients with positive test
results versus 4 events in those with negative test results (2.2%
vs 1.1%, p 5 0.2). By univariate analysis, WMSI at peak dose
reached the highest value (chi-square 15.1, p 5 0.0001). By
stepwise analysis, the most important predictor was again
WMSI at peak dose (chi-square 15.1, hazard ratio [HR] 9.2,
95% confidence interval [CI] 2.85 to 29.7, p , 0.0001),
followed by age (chi-square 6.9, HR 1.08, 95% CI 1.01 to 1.15,
p , 0.009) (Table 3).
Hard cardiac events. When only hard cardiac events (car-
diac death, nonfatal myocardial infarction), were considered,
there were 10 cardiac-related deaths and 11 nonfatal myocar-
dial infarctions in patients with positive test results versus 4
cardiac deaths and 13 nonfatal myocardial infarctions in those
with negative test results (5% vs. 5%, p 5 0.9). Patients with
remote ischemia (9%) had a higher incidence of hard events
than those with homozonal positivity (4%, p , 0.02 vs. remote
ischemia) or negativity for myocardial ischemia (5%, p 5 0.1
vs. remote and homozonal positivity). By univariate analysis,
Table 2. Event Rate Occurrence in Relation to
Dobutamine–Atropine Stress Echocardiographic Results
DASE
p
Value
Positive Findings
(n 5 436)
Negative Findings
(n 5 342)
Cardiac-related death 10 (2.2%) 4 (1.2%) 0.2
Nonfatal MI 11 (2.5%) 13 (4%) 0.3
Unstable angina 40 (9%) 23 (7%) 0.3
Revascularization procedures
(PTCA and CABG)
123 (28%) 51 (15%) 0.001
Data presented are number (%) of patients. CABG5 coronary artery bypass
graft surgery; PTCA 5 percutaneous transluminal coronary angioplasty; other
abbreviations as in Table 1.
Table 3. Stepwise Predictors of Cardiac Death
Chi-Square p Value HR (95% CI)
Peak WMSI 15.1 0.0001 9.2 (2.85–29.7)
Age 6.9 0.009 1.08 (1.01–1.15)
CI 5 confidence interval; HR 5 hazard ratio; WMSI 5 wall motion score
index.
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age yielded the highest predictive value (chi-square 3.6, p 5
0.056), followed by WMSI at peak dose (chi-square 3.35, p 5
0.06) and remote ischemia (chi-square 2.25, p 5 0.1). By
stepwise analysis, the most important predictors were WMSI at
peak stress (chi-square 3.186, HR 2.4, 95% CI 1.07 to 5.62, p,
0.07) and remote ischemia (chi-square 2.89, HR 0.5, 95% CI
0.27 to 1.11, p , 0.08) after age and male gender.
Spontaneous events. Patients with positive test results had a
higher incidence of spontaneous events than those with nega-
tive results, but this difference did not reach statistical signifi-
cance (14% vs. 12%, p 5 0.3 [10 cardiac-related deaths, 11
nonfatal myocardial infarctions, 40 repeat hospital admissions
for unstable angina in patients with positive results vs. 4 cardiac
deaths, 13 nonfatal myocardial infarctions, 23 repeat hospital
admissions for unstable angina in patients with negative re-
sults]). By univariate analysis, the most important predictors
were the presence of myocardial viability (chi-square 9.71, p ,
0.0018), followed by age (chi-square 8.76, p , 0.0031) and
peak WMSI (chi-square 7.86, p , 0.0051). Other variables,
such as lytic therapy versus no lytic therapy (chi-square 0.91,
p 5 0.3) or Q wave versus non-Q wave infarction (chi-square
0.01, p 5 0.9), were not statistically significant.
By stepwise analysis, the most important predictor was
again the presence of myocardial viability (chi-square 9.7, HR
2.0, 95% CI 1.39 to 3.12, p , 0.002), followed by age
(chi-square 11.4, HR 1.03, 95% CI 1.01 to 1.05, p , 0.001). In
Figure 1, the cumulative survival rates free of spontaneously
occurring events in patients with and without myocardial
viability are reported (p , 0.05 between the two groups).
Discussion
In patients evaluated early after a first acute uncomplicated
myocardial infarction, the presence of myocardial viability
detected by dobutamine stress echocardiography is associated
with an increased incidence of unstable angina. The induction
of remote ischemia is associated with an increased incidence of
cardiac-related death and reinfarction—hard events that are
not predicted by the presence of myocardial viability in this
group of patients.
Prognostic meaning of inducible ischemia: comparison
with previous studies. Peak dobutamine WMSI offers an
integrated assessment of the extent and severity of left ventric-
ular dysfunction at peak stress correlated to the extent and
severity of the underlying coronary artery disease (16,18,19)
and is the strongest predictor of subsequent cardiac-related
death. This finding is in keeping with the large body of
evidence from several studies demonstrating the usefulness of
stress echocardiography in risk stratification early after acute
myocardial infarction, using different stressors, such as exercise
(20,21), transesophageal atrial pacing (22) and dipyridamole
(7,23–26). In particular, the presence of extensive myocardial
ischemia detected by dipyridamole stress echocardiography
was associated with subsequent hard cardiac events in a
large-scale multicenter, multinational, observational study in
close to 1,000 patients (7,27), showing that peak WMSI was the
strongest predictor of subsequent cardiac-related death. In the
present study, we found that the stratification capability of
dobutamine-induced ischemia was substantially better for
cardiac-related death than for myocardial infarction or unsta-
ble angina. This finding further emphasizes the pathophysio-
logic heterogeneity of different cardiac events, which cannot all
be predicted by a single variable. Stress testing assesses coro-
nary stenoses by reflecting the physiologic consequences but
cannot predict events largely unrelated to plaque size, such as
thrombus, ulceration or fissuration, which can lead to abrupt
coronary occlusions (28). The risk of reinfarction can be
predicted weakly by inducible wall motion abnormalities (29),
and the newly infarcted area matches the “area at risk”
identified as ischemic during stress echocardiography only in a
minority of cases (30). However, the fatal impact of occlusion
will be very different according to the coronary atherosclerotic
“milieu” detected by stress echocardiographic results.
Prognostic meaning of myocardial viability: comparison
with previous studies. After the pioneering study of Pierard et
al. (8), several groups have confirmed that wall motion re-
sponse to dobutamine in a region with rest dysfunction is highly
sensitive and specific for predicting the functional recovery of
segmental contraction seen at late follow-up echocardiography
(16). In light of this evidence, it would be expected that
myocardial viability would carry a potential positive prognostic
impact. If a segment has an inotropic reserve after dobut-
amine, it is likely to recover, and left ventricular function—a
major prognostic determinant—will improve. In the present
study, myocardial viability, identified as contractile recovery
after low dose dobutamine, predicted the recurrence of angina,
Figure 1. Cumulative survival rates free of spontaneously occurring
events (including death, reinfarction and unstable angina) in patients
with absence (top curve) and presence (bottom curve) of myocardial
viability, recognized as functional improvement in a segment with rest
wall motion abnormalities after low dose dobutamine. The presence of
myocardial viability is associated with a greater incidence of events
(p , 0.05).
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although it was not associated with hard cardiac events. This
finding is in keeping with previous studies (3–6), in which
myocardial viability was identified by nuclear medicine tech-
niques in patients with previous myocardial infarction. In those
studies, myocardial viability showed an adverse prognostic
value, even stronger than residual ischemia (4,6). It is conceiv-
able that residual viable myocardium after myocardial infarc-
tion may act as an unstable substrate for further events unless
it undergoes revascularization (6). In contrast, the beneficial
prognostic effect of functional recovery is mild, if any, in
patients with preserved global left ventricular function, present
on the flat part of the hyperbolic curve relating left ventricular
function to cardiac death (2). Our patients had a mean rest
WMSI of 1.5, indicating preserved left ventricular function.
More recently Williams et al. (6) demonstrated that viable or
ischemic myocardium detected on dobutamine echocardiogra-
phy in patients with left ventricular dysfunction is associated
with an adverse prognosis, consistent with the findings of the
present study showing that echocardiographically assessed
myocardial viability can “paradoxically” affect prognosis in a
negative manner.
Clinical implications. Survivors of acute myocardial infarc-
tion constitute a large, readily identifiable subset of patients in
whom prognosis ultimately depends on the extent of residual
ischemia, left ventricular dysfunction and presence of myocar-
dial viability. Patients with either overt heart failure or ongoing
myocardial ischemia have an adverse outcome and should be
managed with an aggressive diagnostic and therapeutic ap-
proach. In the vast majority of patients who are asymptomatic
after acute myocardial infarction, an early functional evalua-
tion with stressing procedures is mandatory. The viability
information is especially useful in predicting recurrence of
angina. The echocardiographic positivity for ischemia occur-
ring in a territory different from the infarct-related artery and
WMSI at peak stress are more frequently associated with hard
events. Different prognostic end points can be recognized with
variable efficiency by different stress echocardiographic vari-
ables, further emphasizing that the pathophysiologic mecha-
nisms of cardiac-related death, reinfarction and angina are not
likely to be the same (28). The echocardiographic recognition
of myocardial viability is more important for predicting softer
events, whereas recognition of myocardial ischemia is more
important for predicting harder prognostic end points.
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